Dr. John Cush RheumNow
4 years 6 months ago
ICYMI: COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/tg5eETiMO4 https://t.co/bC45AAnP3h
Dr. John Cush RheumNow
4 years 6 months ago
RheumNow Live is Coming to Town!
Have you signed up for RheumNow Live yet? We still have space available. It kicks off one week from today!
https://t.co/mMlAC3OXTJ
https://t.co/DY32PxQnRm https://t.co/kcIQ2GdObr
Dr. John Cush RheumNow
4 years 6 months ago
The Differential on Tenosynovitis
70 yr old man with tenosynovitis - imagine the possibilities
QD Clinic is sponsored by https://t.co/4UQlqwujiR
(March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/HraAZHIKA9 https://t.co/nzG6tlXuJU
Dr. John Cush RheumNow
4 years 6 months ago
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
https://t.co/XYK02MRMp6 https://t.co/LgToS5NCaa
Dr. John Cush RheumNow
4 years 6 months ago
Could Anifrolumab Work in Lupus Nephritis?
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
https://t.co/6EtLf1nhv6 https://t.co/RrJX08vcIK
Dr. John Cush RheumNow
4 years 6 months ago
Study of 177 PsA pts, those with dactylitis had more severe disease with signif. greater SJC, CRP, US-detected synovitis and bone erosions in DMARD-naive early PsA. Dactylitis could be useful in early risk stratification. https://t.co/zUoWSEFxaN
Dr. John Cush RheumNow
4 years 6 months ago
6780 nonspecific MSK pts (no synovitis) saw 3% w/ CCP+, 45% progressed to IA (RA). Progression seen w/ high CCP (OR 9.4), hand (OR 2.7) & foot pain (OR 4.1). CCP- progress if pain in hands (OR 2.5) or knees. 96% NPV for CCP- w/o hand/foot pain https://t.co/FbDIggQFLJ https://t.co/VtvRUOHTnc
Dr. John Cush RheumNow
4 years 6 months ago
What To Do With the NSAID?
Elderly arthritis needs something for pain - what to do with the NSAID?
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/YmGTOVJymm https://t.co/T3Y8LUNHVk
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush RheumNow
4 years 6 months ago
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/Idlqidy04d https://t.co/su3PI5fSaS
Dr. John Cush RheumNow
4 years 6 months ago
CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/nXEBMuSDZL https://t.co/fa9yOqtxiI
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
This double-blind, phase II trial, enrolled 203 patients with active PsA and randomised them to either placebo, deucravacitinib 6 mg once a day or 12 mg once a day. The primary endpoint was the ACR-20 response at week 16.
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
A phase II double-blinded study looked at the efficacy of anifrolumab active, biopsy-proven, Class III/IV lupus nephritis taking background glucocorticoids and mycophenolate mofetil.
